|
|
|
Singapore, May 22, 2008: American pharma giant Merck has discontinued ACHIEVE (An Assessment of Coronary Health Using an Intima-Media Thickness Endpoint for Vascular Effects), an imaging study evaluating MK-0524A (ER niacin/laropiprant) in patients with Heterozygous Familial Hypercholesterolemia...
Full Coverage:
Merck ends cholesterol drug study
Merck & Co has discontinued Achieve, an imaging study evaluating MK-0524A in patients with heterozygous familial hypercholesterolemia. The study was discontinued at the recommendation of the steering committee based on its review and evaluation of scientific data from recent carotid intima-media...
Merck Can't ACHIEVE Anything
By Brian Orelli May 22, 2008 Comments (0) What do you get when you combine a trial design that failed to show improved patient outcomes, two cholesterol-lowering drugs, and an FDA not-approvable letter? Merck (NYSE: MRK) announced yesterday that it was cancelling its ACHIEVE (An Assessment of...
Merck Can't ACHIEVE Anything (at Motley Fool)
By Brian Orelli May 22, 2008 Comments (0) What do you get when you combine a trial design that failed to show improved patient outcomes, two cholesterol-lowering drugs, and an FDA not-approvable letter? Merck (NYSE: MRK) announced yesterday that it was cancelling its ACHIEVE (An Assessment of...
Has Merck Learned Anything from Vioxx and Vytorin?
It's getting tough to find any Merck drug that can hold up to scrutiny. Merck transposed its own clinical study results of 34 deaths in the Vioxx group and 12 in the placebo group to 29 deaths in the Vioxx group and 17 in the placebo group when it submitted data to the FDA, write Bruce Psaty, MD,...
Cholesterol Drug Testing Comes To A Halt
Merck Gives Up On Drug After FDA Ruling TRENTON, N.J. -- The drugmaker said Wednesday an advisory committee recommended ending the study of cholesterol drug MK-0524A, two months after the same scientists urged enrollment of more patients be put on hold. The halted study, called ACHIEVE, used...
Cholesterol Drug Testing Comes To A Halt
Merck stops a study of what it hoped would be a new way to treat high cholesterol. ... Merck Gives Up On Drug After FDA Ruling TRENTON, N.J. -- The drugmaker said Wednesday an advisory committee recommended ending the study of cholesterol drug MK-0524A, two months after...
Cholesterol Drug Testing Comes To A Halt
Merck stops a study of what it hoped would be a new way to treat high cholesterol. ... Merck Gives Up On Drug After FDA Ruling TRENTON, N.J. -- The drugmaker said Wednesday an advisory committee recommended ending the study of cholesterol drug MK-0524A, two months after...
Study Stops Early On Cholesterol Drug
Merck Gives Up On Drug After FDA Ruling TRENTON, N.J. -- The drugmaker said Wednesday an advisory committee recommended ending the study of cholesterol drug MK-0524A, two months after the same scientists urged enrollment of more patients be put on hold. The halted study, called ACHIEVE, used...
Study Stops Early On Cholesterol Drug
Merck Gives Up On Drug After FDA Ruling TRENTON, N.J. -- The drugmaker said Wednesday an advisory committee recommended ending the study of cholesterol drug MK-0524A, two months after the same scientists urged enrollment of more patients be put on hold. The halted study, called ACHIEVE, used...
Study Stops Early On Cholesterol Drug
Merck had hoped a new anti-cholestrol drug would continue its franchise. Instead, testing is called to an end. ... Merck Gives Up On Drug After FDA Ruling TRENTON, N.J. -- Merck has halted a study of an experimental drug it had touted as key to energizing its sagging...
Related categories
Health Care, Medicines & Remedies, Pharmaceuticals, Patients, Cholesterol Drugs, Singapore
International editions
English - US | English - UK | Deutsch | Française | Español | Português | Italiano | Česká | Русский (Russian) | عربي (Arabic) | 中文（简）(Simplified Chinese)Copyright © 2008 Newstin a.s. All rights reserved. 4.2.5,fe-web-4.2.5;commons-4.2.1;api-4.2.1;fe-4.2.3, 10.10.1.27